Yanling Ouyang1, Florian M Heussen1, Amirhossein Hariri2, Pearse A Keane3, SriniVas R Sadda4. 1. Doheny Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, California; Department of Ophthalmology, Charité - Universitätsmedizin Berlin, Germany. 2. Doheny Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, California. 3. NIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, England. 4. Doheny Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, California. Electronic address: sadda@usc.edu.
Abstract
PURPOSE: To use spectral domain optical coherence tomography (SD-OCT) to investigate risk factors predictive for the development of atrophy of drusenoid lesions (DLs) (drusen and drusenoid pigment epithelium detachment) in eyes with non-neovascular age-related macular degeneration (NNVAMD). DESIGN: Cohort study. PARTICIPANTS: Forty-one eyes from 29 patients with NNVAMD. METHODS: Patients with NNVAMD who underwent registered SD-OCT imaging over a minimum period of 6 months were reviewed. Drusenoid lesions that were accompanied by new atrophy onset at 6 months or last follow-up (FUL) were further analyzed. Detailed lesion change was described throughout the study period. Odds ratios (ORs) and risk for new local atrophy onset were calculated. MAIN OUTCOME MEASURES: Drusenoid lesion features and longitudinal changes in features, including maximum lesion height, lesion diameter, lesion internal reflectivity, and presence and extent of overlying intraretinal hyperreflective foci (HRF). Subfoveal choroidal thickness (SFCT) and choroidal thickness (CT) were measured below each lesion. RESULTS: A total of 543 individual DLs were identified at baseline, and 28 lesions developed during follow-up. The mean follow-up time was 21.3±8.6 months (range, 6-44 months). Some 3.2% of DLs (18/571) progressed to atrophy within 18.3 ± 9.5 months (range, 5-28 months) of the initial visit. Drusenoid lesions with heterogeneous internal reflectivity were significantly associated with new atrophy onset at 6 months (OR, 5.614; 95% confidence interval [CI], 1.277-24.673) and new atrophy onset at FUL (OR, 7.005; 95% CI, 2.300-21.337). Lesions with the presence of HRF were significant predictors of new atrophy onset at 6 months (OR, 30.161; 95% CI, 4.766-190.860) and FUL (OR, 11.211; 95% CI, 2.513-50.019). Lesions with a baseline maximum height >80 μm or CT ≤ 135 μm showed a positive association with the new atrophy onset at FUL (OR, 7.886; 95% CI, 2.105-29.538 and OR, 3.796; 95% CI, 1.154-12.481, respectively). CONCLUSIONS: The presence of HRF overlying DLs, a heterogeneous internal reflectivity of these lesions, was found consistently to be predictive of local atrophy onset in the ensuing months. These findings provide further insight into the natural history of anatomic change occurring in patients with NNVAMD.
PURPOSE: To use spectral domain optical coherence tomography (SD-OCT) to investigate risk factors predictive for the development of atrophy of drusenoid lesions (DLs) (drusen and drusenoid pigment epithelium detachment) in eyes with non-neovascular age-related macular degeneration (NNVAMD). DESIGN: Cohort study. PARTICIPANTS: Forty-one eyes from 29 patients with NNVAMD. METHODS:Patients with NNVAMD who underwent registered SD-OCT imaging over a minimum period of 6 months were reviewed. Drusenoid lesions that were accompanied by new atrophy onset at 6 months or last follow-up (FUL) were further analyzed. Detailed lesion change was described throughout the study period. Odds ratios (ORs) and risk for new local atrophy onset were calculated. MAIN OUTCOME MEASURES: Drusenoid lesion features and longitudinal changes in features, including maximum lesion height, lesion diameter, lesion internal reflectivity, and presence and extent of overlying intraretinal hyperreflective foci (HRF). Subfoveal choroidal thickness (SFCT) and choroidal thickness (CT) were measured below each lesion. RESULTS: A total of 543 individual DLs were identified at baseline, and 28 lesions developed during follow-up. The mean follow-up time was 21.3±8.6 months (range, 6-44 months). Some 3.2% of DLs (18/571) progressed to atrophy within 18.3 ± 9.5 months (range, 5-28 months) of the initial visit. Drusenoid lesions with heterogeneous internal reflectivity were significantly associated with new atrophy onset at 6 months (OR, 5.614; 95% confidence interval [CI], 1.277-24.673) and new atrophy onset at FUL (OR, 7.005; 95% CI, 2.300-21.337). Lesions with the presence of HRF were significant predictors of new atrophy onset at 6 months (OR, 30.161; 95% CI, 4.766-190.860) and FUL (OR, 11.211; 95% CI, 2.513-50.019). Lesions with a baseline maximum height >80 μm or CT ≤ 135 μm showed a positive association with the new atrophy onset at FUL (OR, 7.886; 95% CI, 2.105-29.538 and OR, 3.796; 95% CI, 1.154-12.481, respectively). CONCLUSIONS: The presence of HRF overlying DLs, a heterogeneous internal reflectivity of these lesions, was found consistently to be predictive of local atrophy onset in the ensuing months. These findings provide further insight into the natural history of anatomic change occurring in patients with NNVAMD.
Authors: Zohar Yehoshua; Fenghua Wang; Philip J Rosenfeld; Fernando M Penha; William J Feuer; Giovanni Gregori Journal: Ophthalmology Date: 2011-07-02 Impact factor: 12.079
Authors: Giovanni Gregori; Fenghua Wang; Philip J Rosenfeld; Zohar Yehoshua; Ninel Z Gregori; Brandon J Lujan; Carmen A Puliafito; William J Feuer Journal: Ophthalmology Date: 2011-03-09 Impact factor: 12.079
Authors: Catherine Cukras; Elvira Agrón; Michael L Klein; Frederick L Ferris; Emily Y Chew; Gary Gensler; Wai T Wong Journal: Ophthalmology Date: 2010-01-15 Impact factor: 12.079
Authors: Chandrakumar Balaratnasingam; Jeffrey D Messinger; Kenneth R Sloan; Lawrence A Yannuzzi; K Bailey Freund; Christine A Curcio Journal: Ophthalmology Date: 2017-01-30 Impact factor: 12.079
Authors: Arno P Göbel; Monika Fleckenstein; Tjebo F C Heeren; Frank G Holz; Steffen Schmitz-Valckenberg Journal: Graefes Arch Clin Exp Ophthalmol Date: 2015-04-24 Impact factor: 3.117
Authors: Zhichao Wu; Chi D Luu; Lauren N Ayton; Jonathan K Goh; Lucia M Lucci; William C Hubbard; Jill L Hageman; Gregory S Hageman; Robyn H Guymer Journal: Invest Ophthalmol Vis Sci Date: 2015-02-12 Impact factor: 4.799
Authors: Robyn H Guymer; Philip J Rosenfeld; Christine A Curcio; Frank G Holz; Giovanni Staurenghi; K Bailey Freund; Steffen Schmitz-Valckenberg; Janet Sparrow; Richard F Spaide; Adnan Tufail; Usha Chakravarthy; Glenn J Jaffe; Karl Csaky; David Sarraf; Jordi M Monés; Ramin Tadayoni; Juan Grunwald; Ferdinando Bottoni; Sandra Liakopoulos; Daniel Pauleikhoff; Sergio Pagliarini; Emily Y Chew; Francesco Viola; Monika Fleckenstein; Barbara A Blodi; Tock Han Lim; Victor Chong; Jerry Lutty; Alan C Bird; Srinivas R Sadda Journal: Ophthalmology Date: 2019-09-30 Impact factor: 12.079
Authors: Emma C Zanzottera; Jeffrey D Messinger; Thomas Ach; R Theodore Smith; K Bailey Freund; Christine A Curcio Journal: Invest Ophthalmol Vis Sci Date: 2015-05 Impact factor: 4.799
Authors: Anna C S Tan; Polina Astroz; Kunal K Dansingani; Jason S Slakter; Lawrence A Yannuzzi; Christine A Curcio; K Bailey Freund Journal: Invest Ophthalmol Vis Sci Date: 2017-04-01 Impact factor: 4.799